Aza-BODIPY probe for selective visualization of cyclooxygenase-2 in cancer cells†

Thitima Pewklang,‡a Kantapat Chansaenpak,‡b Rung-Yi Lai,‡a Parinya Noisa‡c and Anyanee Kamkaew‡a

AZB-IMC2 was developed as a COX-2 specific probe that exhibited a brighter fluorescence signal in cancer cells that overexpress COX-2 compared to normal cells. Oxidative stress agent-treated normal cells were found to be overexpressed compared to the corresponding normal cells. Therefore, COX-2 has been considered as a promising target for tumor-specific target-based therapeutics. In the past decades, some fluorescence-based COX-2-targeting probes have been developed, however, COX-2-specific cancer biomarker development is still needed for clinical use.

Introduction

Cyclooxygenase (COX), a prostaglandin-endoperoxide synthase, is a family of the two isoenzymes, COX-1 and COX-2, and plays an essential role in the formation of prostanooids. Among the isoenzymes, clinical data revealed that COX-2 is overexpressed in all stages of cancer, from the earliest premalignant phase to metastasis and high levels of COX-2 were found to be upregulated in various types of cancers, such as pancreatic, colon, gastric, stomach, breast, head/neck carcinoma, or inflammatory lesions. Therefore, COX-2 has been considered as a promising target for tumor-specific target-based therapeutics. In the past decades, some fluorescence-based COX-2-targeting probes have been developed, however, COX-2-specific cancer biomarker development is still needed for clinical use.

Indomethacin (IMC), a commercially available nonsteroid anti-inflammatory drug (NSAID), exerts tumor-selective diagnosis and therapeutic potency by targeting COX-derived prostaglandin (PG) biosynthesis. Although IMC is a non-selective COX isoforms inhibitor (COX-1 and COX-2), it becomes more selective after conjugation with fluorescent dyes. For example, indomethacin (IMC) was linked to Nile Blue dye using a hexanediamine linker as a NIR fluorescent imaging probe. The probe showed Golgi localization in cancer cells that overexpressed COX-2. Moreover, this NIR probe preferentially labeled the tumors in vivo, suggesting potential tool for imaging guided surgery. Another study employed a quinolinium-based moiety conjugated to IMC using click chemistry and the conjugate showed remarkable targeted ability towards cancer cells over normal cells regarding the COX-2 levels.

In general, dyes that absorb and emit light in NIR region are ideal to minimize interference from cells autofluorescence, which is a major background noise in cell imaging. However, most currently used NIR-emitting dyes in bioimaging, particularly cyanine-based fluorophores, suffer from inherently low chemical and photostability. These phenomena significantly limit the use of these dyes in long-term optical imaging that requires duration of light exposure in cellular environment. Borondipyromethenes (BODIPYs) and their derivatives, in comparison, contain boron bridge that introduces rigidity to the system leading to prevention of trans–cis isomerization and twisting, enhancing fluorescent quantum yield and photostability of the dyes.

According to the bivalent ligand approach, it was found that duplication pharmacophores leads to an increase in potency of binding recognition compared to the corresponding monovalent ligand. Therefore, in this study, we reported bivalent conjugation of indomethacin to an aza-borondipyromethene (aza-BODIPY) dye, a class of BODIPYs with NIR emission, to enhance COX-2 selectivity (AZB-IMC2).

Aza-BODIPY dye was linked to two molecules of indomethacin using azidotriethyleneglycol linker (Scheme 1). AZB-IMC2 has advantages of optical properties with NIR absorption (λmax ~ 700 nm) and emission (λmax ~ 730 nm) which can detect cancer cells by fluorescence imaging. NIR fluorescent COX-2 inhibitors are attractive candidates as deep-seated tissue targeted imaging agents. Such compounds are nonradioactive and stable, thus, they can be developed conveniently for clinical imaging agents.

Results and discussion

Synthesis of AZB-IMC2

AZB-IMC2 was synthesized according to Scheme 1. Compound 2 was obtained from the reaction of sodium azide with 2-(2-(2-...
chloroethoxy)ethoxy)ethanol that give quantitative yield. After that, 2 was undergone esterification with indomethacin to give compound 3. In another part, amino aza-BODIPY 4 was amide coupled with propiolic acid to obtain alkyne substituted aza-BODIPY 5. Finally, the azide–alkyne Huisgen cycloaddition between the azide 3 and the alkyne 5 was performed to give AZB-IMC2 which was used as a COX-2 specific probe for cancer cells imaging.

Optical properties
AZB-IMC2 showed strong UV-vis-NIR absorption peaking at 704 nm and emitted bright fluorescence peaking at 734 nm in DMSO (Fig. 1). The optical properties were determined under various conditions (DMSO, CHCl3, H2O + 3% Tween-80 and 0.01 M PBS pH 7.4 + 3% Tween-80) however, the absorption and emission maxima did not shift significantly. In water and PBS media, Tween-80, the biocompatible surfactant, was added to increase solubility of the dye (see ESI†). AZB-IMC2 exhibited high quantum yield in organic solvents, whereas low quantum yield was observed in aqueous media (Table 1). This might be the results from hydrophobic nature of the targeting probe leading to aggregation in aqueous medium. As AZB-IMC2 could absorb and emit lights in NIR region, this could be beneficial for deep tissue imaging.

Cell viability
Next, cell viability of AZB-IMC2 were tested in different cell lines including cancer (HeLa, HepG2 and MCF-7) and normal (Hek293, RAW 264.7 and HFF) cells. The cells were treated with various concentrations of AZB-IMC2 ranging from 0–50 μM for 24 h before quantifying cell viability. Fig. 2 showed all the cells remained more than 80% viability at the concentration up to 20 μM while at higher concentration (50 μM) the cell viability reduced to only 50%. This phenomenon might be due to the aggregation of the probe at high concentration. However, the highest concentration we used in the following experiments was 5 μM which all the cells maintained full viability.

Confocal imaging
COX-2-targeting ability of AZB-IMC2 was then investigated in living cells. We selected 6 different cell lines, cancer cells (HeLa, HepG2 and MCF-7) known to overexpress COX-2 and normal cells with lower expression of COX-2 (HEK293, HFF and RAW 264.7). After all the cells exposed to AZB-IMC2, increased fluorescent signals were observed when the time increased. Moreover, the brighter fluorescence was detected in cancer cells compared to normal cells and the differences were obviously observed after 6 h incubation (Fig. 3).

In addition, in cancer cells, the fluorescence was found to be in dose-dependent manner (Fig. 4). We also noticed that 5 μM of AZB-IMC2 was enough for cell internalization and could be used as an indicator to distinguish cancer from normal cell lines.

Fluorescence images of lipopolysaccharide-induced inflammatory cell lines
To expand an application of AZB-IMC2 to detect intracellular COX-2 inflamed cells, HEK-293, RAW 264.7 and fibroblast (HFF)
cell lines were first induced with LPS (lipopolysaccharides) to upregulate COX-2 levels. A
followed incubation with LPS for 12 h, combined with treatment with AZB-IMC2 for 2 h, an
enhanced fluorescence was observed in all cell lines (Fig. 5), indicating that AZB-IMC2 could
be used to monitor the oxidative stress in the living system.

Moreover, to evaluate the selectivity towards cancer cells over normal cells via COX-2 mediated
endocytosis upon binding to indomethacin units, the COX-2 blocking experiments were
performed. Cancer cells were incubated with 10 µM and 20 µM of potent COX-2 specific
inhibitors (aceclofenac and celecoxib) for 3 h to down-regulate COX-2 levels before adding
AZB-IMC2. Fig. 6 shows that all cancer cells (HeLa, HepG2 and MCF-7) incubated with AZB-IMC2 in the absence of COX-2 inhibitors exhibited bright fluorescence, whereas, a significant reduction in the fluorescent intensity was observed when the cells exposed to COX-2 inhibitors prior to AZB-IMC2 treatment. Moreover, the fluorescence intensity decreased with increasing amount of celecoxib and aceclofenac, implying that celecoxib and aceclofenac prevented the labeling of cancer cells by AZB-IMC2. Therefore, the indomethacin-conjugated probe AZB-IMC2 displayed a clear relationship with COX-2 expression levels.

Conclusions

In summary, we successfully developed the COX-2 specific probe (AZB-IMC2) for NIR cancer imaging. AZB-IMC2 contained two moieties of indomethacin showing strong absorption and fluorescence in the NIR region (above 700 nm). AZB-IMC2 was not harmful to both cancer (HeLa, HepG2 and MCF-7) and normal (Hek293, RAW 264.7 and HFF) cells at the concentration up to 20 µM. Moreover, as shown in confocal images, AZB-IMC2 exhibited high selectivity towards cancer cells where COX-2 is overexpressed after at least 3 h incubation. In addition, LPS-treated inflamed cell lines (Hek293, RAW 264.7 and HFF) showed enhanced fluorescence as COX-2 level was upregulated. On the other hand, inhibition of COX-2 levels in cancer cells caused significant decreasing of fluorescent signals. These results confirmed that AZB-IMC2 responded to COX-2 expression level of the cells, which can be useful in development of a COX-2-specific cancer biomarker for clinical applications.

Experimental

Materials and instruments

All glassware was oven-dried prior to use. All the reagents have been purchased from the commercially sources (Sigma Aldrich, TCI, Carlo Erba, Acros, Merck) and used without further
purity. Column chromatography purifications were performed using silica gel for chromatography (Carlo Erba) as a stationary phase. Analytical thin layer chromatography (TLC) was performed on TLC silica gel 60 F254 (Merck) and visualized with UV cabinet. 1H NMR and 13C NMR spectra were recorded on Bruker-500 MHz spectrometer at room temperature. Chemical shifts of 1H NMR spectra were recorded and reported in ppm from the solvent resonance (CDCl3 at 7.26 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constants, and number of protons. 13C NMR spectra were also recorded in ppm from the solvent resonance (CDCl3 at 77.23 ppm). MS were measured under ESI and MALDI conditions.

Synthetic procedures

Synthesis of 2-(2-(2-azidoethoxy)ethoxy)-ethyl-2-(1-benzoyl-5-methoxy-2-methyl-1H-indol-3-yl)acetate (3). To solution of 2 (0.2498 g, 1.474 mmol) in dry dichloromethane (DCM, 5 mL) was added indomethacin (0.4904 g, 1.371 mmol). The reaction mixture was cooled to 0 °C. Then, N,N-di-cyclohexylcarbodiimide (DCC, 0.4400 g, 2.132 mmol) and 4-dimethylaminopyridine (DMAP, 30 mg, 0.24 mmol) were added into the mixture containing: carbodiimide (EDC, 200 mg, 1.04 mmol) and 4-dimethylaminopyridine (DMAP, 48.2 mg, 0.394 mmol) were added into the mixture at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 24 h. After that, the reaction was filtered through Celite® with DCM as eluent. The organic layer was dried over anhydrous Na2SO4.T he solvent was then removed under reduced pressure. The obtained residue was purified by silica chromatography eluting with hexane : EtOAc (1 : 1 to 1 : 3), followed by DCM : MeOH (95 : 5) to yield 20 mg (15% of AZB-IMC2) as a dark green solid. 1H NMR (500 MHz, CDCl3): δ = 8.97 (s, 1H), 8.35 (s, 1H), 8.29 (s, 1H), 8.08 (d, J = 8.8 Hz, 2H), 7.84 (d, J = 7.8 Hz, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.59 (s, 1H), 7.57 (s, 1H), 7.45–7.40 (m, 1H), 7.07 (s, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.92 (s, 1H), 6.81 (d, J = 9.0 Hz, 2H), 6.60 (d, J = 8.9 Hz, 1H), 4.58 (s, 2H), 4.26 (t, J = 4.6 Hz, 2H), 4.05–4.04 (m, 2H), 3.87 (s, 3H), 3.81 (m, 2H), 3.76 (s, 3H), 3.66–3.63 (m, 2H), 3.54–3.52 (m, 2H), 3.45 (t, J = 3.7 Hz, 2H), 2.31 (s, 3H). 13C NMR (500 MHz, CDCl3): δ = 170.9, 168.3, 153.4, 153.3, 143.1, 134.0, 131.2, 131.2, 129.2, 115.0, 112.6, 111.7, 101.5, 70.7, 70.6, 70.1, 69.2, 64.2, 55.8, 50.7, 30.3, 13.5 ppm. MS (ESI+ m/z): the calculated value (calcd) for [M + Na]+: 537.15, found 537.15.

Synthesis of N,N’-(5,5-difluoro-3,7-bis(4-methoxyphenyl)-5H-4,14,41,54-dipyrrolo[1,2-c:2’,1’f][1,3,5,2]triazaborinine-1,9-diyli)bis(3,1-phenylene)dipropiolamide (5). To solution of 4 (145 mg, 0.247 mmol) in dry dichloromethane (DCM, 5 mL) was added propionic acid (0.06 mL, 1 mmol, 8.6 eq.). The reaction mixture was then cooled to 0 °C. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, 200 mg, 1.04 mmol) and 4-dimethylaminopyridine (DMAP, 30 mg, 0.24 mmol) were added into the mixture at 0 °C. The reaction mixture was allowed to warm to room temperature and stirred for 24 h. After that, the reaction was filtered through Celite® with DCM as eluent. The organic layer was washed with HCl (0.2 N, 1 × 20 mL), NaOH (0.2 N, 2 × 20 mL) and brine (20 mL), respectively. The organic layer was then dried over anhydrous Na2SO4 and the solvent was removed under reduced pressure. The obtained residue was purified by silica chromatography eluting with hexane : EtOAc (1 : 1 to 1 : 3) to yield 69 mg (40%) of 5 as a dark green solid. 1H NMR (500 MHz, CDCl3): δ = 8.50 (s, 1H), 8.03–8.01 (m, 2H), 7.90 (d, J = 8.7 Hz, 1H), 7.74–7.68 (m, 1H), 7.50 (s, 1H), 7.39–7.37 (m, 1H), 6.96 (d, J = 8.7 Hz, 2H), 6.64 (s, 1H), 3.86 (s, 3H), 2.97 (s, 1H). 13C NMR (500 MHz, CDCl3): δ = 162.3, 161.2, 150.0, 145.4, 142.2, 137.6, 133.5, 132.0, 131.4, 129.5, 126.1, 121.2, 119.4, 114.5, 114.1, 75.4, 74.8, 55.7 ppm. MS (MALDI-TOF) m/z: the calculated value (calcd) for C40H28BF2N5NaO4 ([M + Na]+): 714.21, C40H28BF2KN5O4 ([M + K]+): 750.18, found 714.27, 730.23.

UV/vis and fluorescence spectroscopic methods

All the UV/vis absorption spectra and fluorescence were recorded on UV-vis Spectrophotometer (Agilent Technologies Cary 300) and Spectrofluorometer (PerkinElmer LS55), respectively. In both experiments, stock solutions (350 μM) of AZB-IMC2 probe was prepared in DMSO. 10 μM solutions of probes in chloroform, DMSO, DI water, and 0.01 M PBS buffer (pH 7.4) with 3% DMSO were prepared as working solutions. For fluorescence experiments, the emission spectra were recorded at excitation wavelength of 670 nm.

Cell culture

Human cervical cancer (HeLa), human hepatoma cell cancer (HepG2), Michigan Cancer Foundation-7 (MCF-7), human
embryonic kidney 293 (HEK-293), Human Foreskin Fibroblast (HFF), and RAW264.7 cell lines were cultured on 75 cm² culture flasks in Dulbecco’s Modified Eagle’s Media (Hyclone) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Corning). All the cells were cultured at 37 °C in a humidified 95% air, 5% CO₂ atmosphere.

**Cell viability assay**

The cells were seeded on 96-well plate approximately 7 × 10³ cells per well and incubated in completed media for 24 h. Thereafter, the cells were treated with 0, 0.5, 5, 10, 20, 50 μM of AZB-IMC₂ and continued culturing for 24 h. After incubation, the cells were washed with 0.01 M PBS (3 times) and treated with 20 μL of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTT, Sigma-Aldrich) for 2 h. After media removal, DMSO was added to dissolve formazan product. The cell’s viabilities were detected through UV-vis absorption of formazan at wavelength 560 nm.

**Time dependent internalization**

HeLa, HepG2, MCF-7, HEK-293, HFF and RAW 294.7 cells, approximately 1 × 10⁴ cells, were seeded on 8-well chambered coverglass (LabTek, Nunc) and incubated in completed media for 24 h. After that, the cells were treated with 5 μM of AZB-IMC₂ for 0, 1, 3, 6, 24 h. After incubation, the cells were washed with 0.01 M PBS (3 times) and treated with 0.5 μg mL⁻¹ of Hoechst 33342 containing media. The cells were imaged by Laser Scanning Confocal Microscope (Nikon A1Rsi).

**Dose dependent internalization**

HeLa, HepG2, MCF-7 cells, approximately 1 × 10⁴ cells, were seeded on 8-well chambered coverglass and incubated in completed media for 24 h. After that, the cells were treated with 2.5 and 5.0 μM of AZB-IMC₂ probe for 3 h. After incubation, the cells were washed with 0.01 M PBS (3 times) and treated with 0.5 μg mL⁻¹ of Hoechst 33342 containing media. The cells were visualized by Laser Scanning Confocal Microscope (Nikon A1Rsi).

**LPS-induced inflammation experiment**

To study inflammation effects, HEK-293, HFF and RAW 294.7 were seeded on 8-well chambered coverglass and incubated for 24 h. After that, the cells were treated with 1 μg mL⁻¹ lipopolysaccharides (LPS, O111:B4, Sigma) in DMEM for 12 h. After incubation in LPS containing media, the cells were washed three times with 0.01 M PBS and treated with 5 μM of AZB-IMC₂ for 2 h. Before imaging, the cells were washed three times with 0.01 M PBS and treated with 0.5 μg mL⁻¹ of Hoechst 33342 containing media.

**COX-2 blocking experiment**

To study inhibition effect of COX-2 with blocking, HeLa, HepG2, and MCF-7 cells were incubated with 10 μM and 20 μM of aceclofenac and celecoxib (Tokyo Company Industry) for 3 h before being treated with 5 μM of AZB-IMC₂ and incubated for another 3 h. Thereafter, the cells were washed with 0.01 M PBS three times and treated with 0.5 μg mL⁻¹ of Hoechst 33342 containing media before visualization by Laser Scanning Confocal Microscope (Nikon A1Rsi).

**Conflicts of interest**

There are no conflicts to declare.

**Acknowledgements**

This research was supported by SUT Research and Development Fund.

**Notes and references**

1. F. A. Fitzpatrick, *Curr. Pharm. Des.*, 2004, **10**, 577–588.
2. K. Subbaramaiah and A. J. Dannenberg, *Trends Pharmacol. Sci.*, 2003, **24**, 96–102.
3. M. Breining, P. Schirmacher and M. A. Kern, *Curr. Pharm. Des.*, 2007, **13**, 3305–3315.
4. K. Echizen, O. Hirose, Y. Maeda and M. Oshima, *Cancer Sci.*, 2016, **107**, 391–397.
5. M. J. Edelman, L. Hodgson, X. Wang, R. A. Kratzke and E. E. Vokes, *J. Clin. Oncol.*, 2012, **30**, 2019–2020.
6. H. S. Kim, A. Sharma, W. X. Ren, J. Han and J. S. Kim, *Biomaterials*, 2018, **185**, 63–72.
7. M. L. Nasi and M. Castiglione, *Ann. Oncol.*, 2002, **13**, 1169–1171.
8. S. Nath, L. D. Roy, P. Grover, S. Rao and P. Mukherjee, *Pancras*, 2015, **44**, 909–917.
9. A. Thiel, J. Mrena and A. Ristimaki, *Cancer Metastasis Rev.*, 2011, **30**, 387–395.
10. D. Wang and R. N. Dubois, *Oncogene*, 2010, **29**, 781–788.
11. Z. Khan, N. Khan, R. P. Tiwari, N. K. Sah, G. Prasad and P. S. Bisen, *Curr. Drug Targets*, 2011, **12**, 1082–1093.
12. R. de Souza Pereira, *Recent Pat. Anticancer Drug Discov.*, 2009, **4**, 157–163.
13. E. F. de Vries, *Curr. Pharm. Des.*, 2006, **12**, 3847–3856.
14. J. F. Evans and S. L. Kargman, *Curr. Pharm. Des.*, 2004, **10**, 627–634.
15. H. R. Herschman, J. J. Talley and R. DuBois, *Mol. Imaging Biol.*, 2003, **5**, 286–303.
16. L. Milas, *Am. J. Clin. Oncol.*, 2003, **26**, S66–S69.
17. K. Chansaenpak, M. Wang, S. Liu, Z. Wu, H. Yuan, P. S. Conti, Z. Li and F. P. Gbabai, *RSC Adv.*, 2016, **6**, 23126–23133.
18. K. Chansaenpak, B. Vareb and F. P. Gbabai, *Chem. Soc. Rev.*, 2016, **45**, 954–971.
19. A. Bhardwaj, J. Kaur, F. Wuest and E. E. Knaus, *ChemMedChem*, 2014, **9**, 109–116.
20. Y. Ti, L. Yu, Y. Tang, T. Jin, M. Yang, R. Wang, Y. Xu and W. Zhu, *Sens. Actuators B*, 2018, **265**, 582–590.
21. M. J. Uddin, B. C. Crews, A. L. Blobaum, P. J. Kingsley, D. L. Gorden, J. O. McIntyre, L. M. Matrisian, K. Subbaramaiah, A. J. Dannenberg, D. W. Piston and L. J. Marnett, *Cancer Res.*, 2010, **70**, 3618–3627.
22 M. J. Uddin, B. C. Crews, K. Ghebreselasie and L. J. Marnett, *Bioconjugate Chem.*, 2013, **24**, 712–723.

23 H. Zhang, J. Fan, J. Wang, B. Dou, F. Zhou, J. Cao, J. Qu, Z. Cao, W. Zhao and X. Peng, *J. Am. Chem. Soc.*, 2013, **135**, 17469–17475.

24 H. Zhang, J. Fan, J. Wang, S. Zhang, B. Dou and X. Peng, *J. Am. Chem. Soc.*, 2013, **135**, 11663–11669.

25 Q. Zhang, Z. Han, J. Tao, W. Zhang, P. Li, L. Tang and Y. Gu, *J. Biophotonics*, 2018, **11**, e201700339.

26 R. J. Flower, *Nat. Rev. Drug Discovery*, 2003, **2**, 179–191.

27 M. G. Papich, in *Saunders Handbook of Veterinary Drugs*, ed. M. G. Papich and W. B. Saunders, St. Louis, 2016, pp. 396–397, DOI: 10.1016/b978-0-323-24485-5.00307-7.

28 J. H. Jang, H. Lee, A. Sharma, S. M. Lee, T. H. Lee, C. Kang and J. S. Kim, *Chem. Commun.*, 2016, **52**, 9965–9968.

29 H. S. Kim, T. Park, W. X. Ren, J. Y. Lim, M. Won, J. S. Heo, S. G. Lee and J. S. Kim, *Dyes Pigm.*, 2018, **150**, 261–266.

30 B. Wang, J. Fan, X. Wang, H. Zhu, J. Wang, H. Mu and X. Peng, *Chem. Commun.*, 2015, **51**, 792–795.

31 H. Zhang, J. Fan, K. Wang, J. Li, C. Wang, Y. Nie, T. Jiang, H. Mu, X. Peng and K. Jiang, *Anal. Chem.*, 2014, **86**, 9131–9138.

32 C. Shi, J. B. Wu and D. Pan, *Review on near-infrared heptamethine cyanine dyes as theranostic agents for tumor imaging, targeting, and photodynamic therapy*, SPIE, 2016.

33 S. Luo, E. Zhang, Y. Su, T. Cheng and C. Shi, *Biomaterials*, 2011, **32**, 7127–7138.

34 S. A. Soper and Q. L. Mattingly, *J. Am. Chem. Soc.*, 1994, **116**, 3744–3752.

35 A. Kamkaew, S. H. Lim, H. B. Lee, L. V. Kiew, L. Y. Chung and K. Burgess, *Chem. Soc. Rev.*, 2013, **42**, 77–88.

36 A. Loudet and K. Burgess, *Chem. Rev.*, 2007, **107**, 4891–4932.

37 N. Boens, V. Lean and W. Dehaen, *Chem. Soc. Rev.*, 2012, **41**, 1130–1172.

38 R. Ziessel, G. Ulrich and A. Harriman, *New J. Chem.*, 2007, **31**, 496–501.

39 A. P. Tamiz, J. Zhang, M. Zhang, C. Z. Wang, K. M. Johnson and A. P. Kozikowski, *J. Am. Chem. Soc.*, 2000, **122**, 5393–5394.

40 M. Rosini, E. Simoni, M. Bartolini, E. Soriano, J. Marconcetelles, V. Andrisano, B. Monti, M. Windisch, B. Hutter-Pair, D. W. McClymont, I. R. Mellor and M. L. Bolognesi, *ChemMedChem*, 2013, **8**, 1276–1281.

41 I. Raji, F. Yadudu, E. Janeira, S. Fathi, L. Szymczak, J. R. Kornacki, K. Komatsu, J. D. Li, M. Mrksich and A. K. Oyelere, *Bioorg. Med. Chem.*, 2017, **25**, 1202–1218.

42 P. S. Portoghese, *J. Med. Chem.*, 2001, **44**, 2259–2269.

43 S. Howorka, J. Nam, H. Bayley and D. Kahne, *Angew. Chem., Int. Ed. Engl.*, 2004, **43**, 842–846.

44 T. Birnkammer, A. Spickenreither, I. Brunskole, M. Lopuch, N. Kagermeier, G. Bernhardt, S. Dove, R. Seifert, S. Elz and A. Buschauer, *J. Med. Chem.*, 2012, **55**, 1147–1160.

45 Y. Ge and D. F. O’Shea, *Chem. Soc. Rev.*, 2016, **45**, 3846–3864.

46 Y. R. Baker, W. R. Galloway, J. T. Hodgkinson and D. R. Spring, *Molecules*, 2013, **18**, 11783–11796.

47 A. Kamkaew and K. Burgess, *Chem. Commun.*, 2015, **51**, 10664–10667.

48 G. Totzke, K. Schulze-Osthoff and R. U. Janicke, *Oncogene*, 2003, **22**, 8021–8030.

49 S. S. Solanki and R. Dahima, *J. Adv. Pharm. Technol. Res.*, 2011, **2**, 128–131.

50 J. L. Mateos, *Drugs Today*, 2010, **46**(suppl. A), 1–25.